TELA Bio Reports Slowed Q1 Revenue Growth, Increased Net Loss Amid Nasdaq Delisting Concern
TELA sits 99% above its 52-week low of $0.501.
Summary
TELA Bio reported modest 3% revenue growth and a higher net loss for Q1 2026, intensifying concerns as its stock remains below the Nasdaq minimum bid price, despite management reiterating full-year guidance.
Key Events · Earnings and Guidance · TELA
-
Q1 2026 Financial Performance
Revenue grew a modest 3% year-over-year to $19.1 million, a significant slowdown from 2025's 16% growth, while net loss increased to $12.3 million.
-
Reiterated Full-Year Guidance
Management maintained its projection for at least 8% revenue growth for full-year 2026, implying an expected acceleration in performance after a weak first quarter.
-
Nasdaq Compliance Pressure
The modest Q1 results add pressure to the company's ongoing efforts to regain compliance with Nasdaq's $1.00 minimum bid price requirement, following a deficiency letter in March.
-
New Product Launch
TELA Bio announced the U.S. commercial launch of OviTex LTR, a fully resorbable hernia repair solution, on April 1st, expanding its product portfolio.
Analysis · TELA · Industrial Applications And Services
TELA Bio's first-quarter 2026 results show a significant deceleration in revenue growth to 3% year-over-year, coupled with an increased net loss. This performance is concerning, especially as the company is currently under a Nasdaq deficiency notice for its stock trading below $1.00. While management reiterated its full-year revenue growth guidance of at least 8%, implying a strong recovery in subsequent quarters, the immediate financial performance adds pressure to its compliance efforts.
At the time of this filing, TELA was trading at $1.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $45.6M. The 52-week trading range was $0.50 to $2.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.